Insider Selling: SiBone (NASDAQ:SIBN) Insider Sells 3,247 Shares of Stock

November 7, 2026 by InsiderTrades.com

Key Points

CEO Laura Francis sold 75,000 SiBone shares at an average $25.30, totaling about $1.90 million; the sale reduced her ownership by 19.78%, leaving her with 304,256 shares.
SiBone’s third-quarter loss of $0.08 per share was narrower than analysts’ expected $0.13 loss, and revenue of $55.7 million slightly topped estimates. The company reaffirmed its 2026 revenue outlook of $231 million to $233 million.
Analysts maintained a broadly positive view, with UBS and TD Cowen raising price targets to $26 and $23, respectively; the consensus rating was “Moderate Buy” with a $25 target.

SiBone (NASDAQ:SIBN - Get Free Report) insider Anshul Maheshwari sold 3,247 shares of the stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $25.00, for a total value of $81,175.00. Following the transaction, the insider owned 211,250 shares of the company's stock, valued at approximately $5,281,250. This trade represents a 1.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

4 Recent Earnings Winners Riding Fresh Momentum in May

Anshul Maheshwari also recently made the following trade(s):

On Thursday, October 29th, Anshul Maheshwari sold 3,738 shares of SiBone stock. The shares were sold at an average price of $22.50, for a total value of $84,105.00.
On Monday, October 5th, Anshul Maheshwari sold 1,731 shares of SiBone stock. The shares were sold at an average price of $19.50, for a total value of $33,754.50.
On Friday, October 2nd, Anshul Maheshwari sold 3,318 shares of SiBone stock. The shares were sold at an average price of $18.18, for a total value of $60,321.24.
On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The stock was sold at an average price of $20.11, for a total value of $233,999.96.
On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total value of $224,784.56.
On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The stock was sold at an average price of $19.55, for a total value of $112,353.85.
On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The shares were sold at an average price of $18.65, for a total value of $87,002.25.

SiBone Stock Down 0.1%

NASDAQ SIBN traded down $0.03 during trading on Friday, hitting $24.24. The stock had a trading volume of 683,472 shares, compared to its average volume of 654,887. The company has a market capitalization of $1.08 billion, a PE ratio of -78.19 and a beta of 0.64. The company's 50-day moving average price is $19.81 and its two-hundred day moving average price is $16.59. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15. SiBone has a 12 month low of $11.48 and a 12 month high of $25.92.

SiBone (NASDAQ:SIBN - Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05. The firm had revenue of $55.70 million during the quarter, compared to the consensus estimate of $55.31 million. SiBone had a negative return on equity of 7.62% and a negative net margin of 6.20%. As a group, sell-side analysts forecast that SiBone will post -0.34 EPS for the current year.

SiBone News Summary

Here are the key news stories impacting SiBone this week:

Positive Sentiment: Quarterly results beat expectations and lifted shares. Si-Bone reported a third-quarter loss of $0.08 per share, narrower than the $0.13 loss analysts expected, while revenue of $55.7 million modestly exceeded estimates. The results were followed by a reported 8.7% stock jump. Article on SIBN’s post-earnings gain
Positive Sentiment: Analyst support helped drive the stock to a 52-week high. TD Cowen raised its price target to $23 from $20, and UBS raised its target to $26 from $25; both maintained Buy ratings. SIBN reached a 52-week high amid the favorable coverage and earnings momentum. Article on SIBN’s 52-week high and analyst upgrade TD Cowen price-target article UBS price-target article
Neutral Sentiment: Full-year revenue guidance was reaffirmed. Si-Bone’s 2026 revenue outlook of $231 million to $233 million was broadly in line with analyst expectations, offering limited new information for investors. Si-Bone Q3 results and guidance
Negative Sentiment: Multiple insiders sold shares. CEO Laura Francis sold 75,000 shares, SVP Michael Pisetsky sold 36,241, Anshul Maheshwari sold 3,247, and director Jeffrey Dunn sold 20,000. The sales may weigh on sentiment, although each retained shares after the transactions. CEO sale filing SVP sale filing Maheshwari sale filing Dunn sale filing

Institutional Trading of SiBone

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. First Light Asset Management LLC lifted its holdings in shares of SiBone by 51.8% in the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company's stock valued at $132,649,000 after purchasing an additional 2,774,795 shares in the last quarter. Granahan Investment Management LLC grew its holdings in SiBone by 97.6% during the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company's stock worth $21,965,000 after buying an additional 858,942 shares in the last quarter. Paradigm Capital Management Inc. NY raised its position in SiBone by 113.3% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company's stock valued at $14,228,000 after buying an additional 598,300 shares during the last quarter. Dimensional Fund Advisors LP raised its position in SiBone by 41.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company's stock valued at $7,816,000 after buying an additional 182,465 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in SiBone by 101.6% in the 1st quarter. Renaissance Technologies LLC now owns 472,619 shares of the company's stock valued at $5,969,000 after buying an additional 238,219 shares during the last quarter. 98.11% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on SIBN shares. Wall Street Zen raised shares of SiBone from a "hold" rating to a "buy" rating in a report on Saturday. Citigroup restated a "market outperform" rating on shares of SiBone in a research report on Tuesday. UBS Group lifted their price objective on SiBone from $25.00 to $26.00 and gave the stock a "buy" rating in a research note on Tuesday. Weiss Ratings upgraded SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, August 20th. Finally, Truist Financial lifted their price objective on shares of SiBone from $23.00 to $25.00 and gave the company a "buy" rating in a research note on Wednesday, October 14th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, SiBone currently has an average rating of "Moderate Buy" and an average target price of $25.00.

Read Our Latest Research Report on SiBone

SiBone Company Profile

(Get Free Report)

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.